Cargando...
Suppression of autophagy by BCR/ABL
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a “reservoir” o...
Guardado en:
| Publicado en: | Front Biosci (Schol Ed) |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405106/ https://ncbi.nlm.nih.gov/pubmed/22202070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2741/278 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|